Additionally, therapies targeting adenosine axis such as anti-CD38 and anti-CD73 inhibitors succeeded in overcoming resistance associated with ICIs through their potential to increase the infiltration of intratumoral effector CD4+ T cells, enhance the expression of granzyme B and IFN-γ by tumor-infiltrating CD8+ T cells and decrease the accumulation of the immunosuppressive MDSCs and Tregs within the TME (95, 96). Here, CD8A is linked to neoplasm.